{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T12:10:04Z","timestamp":1749816604375,"version":"3.41.0"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>To complete the psychometric validation and scale derivation of the International Consultation on Incontinence Questionnaire\u2010Underactive Bladder (ICIQ\u2010UAB).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The developmental ICIQ\u2010UAB was administered within a Phase II randomised controlled trial of a drug for the treatment of underactive bladder at baseline and follow\u2010up 4 weeks after the start of trial medication treatment. Descriptive analyses and exploratory factor analyses (EFAs) informed the derivation of scored domains for symptoms, health\u2010related quality of life (HRQoL), and associated bother items. The reliability was assessed by Cronbach's \u03b1, while validity was assessed via the correlation with other concurrently administered PROMs at baseline. Responsiveness was evaluated using the change in mean scores from baseline to follow\u2010up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 132 male and female patients with the symptomatic and urodynamic characteristics of detrusor underactivity were enrolled in the analysis. Descriptive analyses and EFAs informed scored domains for 11 symptom items with associated bother, and 7 HRQoL items with associated bother. A further 8 unscored symptom items and one overall HRQL item were retained for their clinical utility. Sensitivity of the ICIQ\u2010UAB to the severity of the condition was supported (known groups validity), and correlations with concurrent PROMs were as expected, showing evidence of construct validity. All domains demonstrated reliability (Cronbach's \u03b1\u2009\u2265\u20090.88). Limited evidence for responsiveness was found, which was likely due to insufficient efficacy of trial medication treatment over administration time\u2010points.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The two scored domains and associated bother for the ICIQ\u2010UAB have been shown to be reliable, valid and sensitive to the severity of the condition. The instrument can be recommended to researchers and clinicians for the comprehensive assessment of symptoms and their impact on HRQoL on patients with suspected UAB.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.70065","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T07:30:52Z","timestamp":1745911852000},"page":"1099-1108","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychometric Validation and Scale Derivation of the ICIQ\u2010Underactive Bladder Patient Reported Outcome Measure"],"prefix":"10.1002","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7486-2322","authenticated-orcid":false,"given":"Alan","family":"Uren","sequence":"first","affiliation":[{"name":"Bristol Urological Institute Southmead Hospital Bristol UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikki","family":"Cotterill","sequence":"additional","affiliation":[{"name":"School of Health and Social Wellbeing, College of Health, Science and Society University of the West of England Bristol UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth D.","family":"Bacci","sequence":"additional","affiliation":[{"name":"Patient\u2010Centered Research Evidera Wilmington North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-131X","authenticated-orcid":false,"given":"Karin","family":"Coyne","sequence":"additional","affiliation":[{"name":"Patient\u2010Centered Research Evidera Wilmington North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zalmai","family":"Hakimi","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe B.V. Leiden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Doyle","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe B.V. Leiden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Atzinger","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe B.V. Leiden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. W. Olivier","family":"van Till","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe B.V. Leiden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2776-2200","authenticated-orcid":false,"given":"Paul","family":"Abrams","sequence":"additional","affiliation":[{"name":"Bristol Urological Institute Southmead Hospital Bristol UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23701"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.03.045"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.4111\/kju.2012.53.5.342"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.11.019"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.10.015"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.5152\/tud.2019.37659"},{"key":"e_1_2_12_9_1","unstructured":"FDA. \"Guidance for Industry: Patient\u2010Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims \"U.S. Food and Drug Administration Published online December2009."},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23947"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.24931"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2003.12.027"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.00461.x"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199603000-00003"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.379"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016370925601"},{"volume-title":"Factor Analysis","year":"1983","author":"Gorsuch R.","key":"e_1_2_12_18_1"},{"key":"e_1_2_12_19_1","first-page":"248","volume-title":"In: Psychometric Theory","author":"Nunnally J.","year":"1994"},{"volume-title":"Mplus User's Guide","author":"L K. M.","key":"e_1_2_12_20_1"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00422218"},{"volume-title":"Applied Statistics for the Behavioral Sciences","year":"2021","author":"Hinkle D. E.","key":"e_1_2_12_22_1"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.09.024"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.012"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.08.014"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23492"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.70065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:42:56Z","timestamp":1749814976000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.70065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/nau.70065"],"URL":"https:\/\/doi.org\/10.1002\/nau.70065","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"type":"print","value":"0733-2467"},{"type":"electronic","value":"1520-6777"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"2024-08-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}